Xeris Biopharma (XERS) Stock Forecast & Price Target

XERS$16.80—
BiotechnologyGrowth StockHigh Quality
Compare
Market cap$3.10BEnterprise value—Revenue (TTM)$368.26MMarket position—

Score

65
Bullish
Value
32
Quality
70
Growth
94

Xeris Biopharma Holdings, Inc. price target

XERS
Low$14.00
Average$15.00
High$16.00
Upside vs current price-10.7%

The average target of $15.00 is -10.7% versus the current XERS price of $16.80.

Xeris Biopharma Holdings, Inc. analyst ratings

RatingAnalysts
Strong buy1
Buy5
Hold1
Sell0
Strong sell0
ConsensusBuy

7 analysts cover XERS.

Xeris Biopharma Holdings, Inc. EPS and revenue estimates

The estimate table for the Xeris Biopharma Holdings, Inc. keeps 2026 EPS $-0.02, 2027 EPS $0.42, and years with fewer than three analysts are not filled in.

Fiscal yearEPS estimateRevenue estimate
2026$-0.02$401.51M
2027$0.42$526.63M

Is Xeris Biopharma Holdings, Inc. a buy or sell?

Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a buy (1 strong buy and 5 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The XERS consensus label is Buy, beside 6 buy-side ratings and 0 sell-side ratings.

The average target of $15.00 implies -10.7% versus the current price of $16.80.

the Xeris Biopharma Holdings, Inc. closes with 6 buy-side ratings and 0 on the sell side. The headcount is Buy.

Reading the Xeris Biopharma Holdings, Inc. forecast

There is little daylight between XERS targets. Low $14.00, average $15.00, high $16.00.

From today's $16.80 print, the XERS average target is -10.7% away.

Most of the XERS coverage agrees: 6 of 7 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.

Earnings estimates for XERS are rising: 2026 $-0.02, then 2027 $0.42.

XERS target coverage is thin at 3 firms, and one revision moves the band.

Xeris Biopharma Holdings, Inc. forecast questions

What is the XERS price target?

The published range for XERS is $14.00 to $16.00, with a average target of $15.00. That average is -10.7% versus the current price of $16.80.

Is Xeris Biopharma Holdings, Inc. a buy or sell?

Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, which for XERS is 6 on the buy side, 1 at hold, and 0 on the sell side.

What is the EPS estimate for Xeris Biopharma Holdings, Inc.?

Analyst EPS estimates for Xeris Biopharma Holdings, Inc.: 2026 $-0.02, 2027 $0.42.

What is the revenue estimate for Xeris Biopharma Holdings, Inc.?

Analyst revenue estimates for Xeris Biopharma Holdings, Inc.: 2026 $401.51M, 2027 $526.63M.

How many analysts cover XERS?

7 analysts cover XERS. Their consensus on XERS is Buy, across those 7.

XERS price $16.80 —

Insights · Forecast · Financials · Learn

Stocklytics home · Screener